Raymond James & Associates’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

Raymond James & Associates’s Portfolio NVIV Stock Details NVIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-4	Closed	-$40K	–	3730
2018 Q1	$40K	Hold	4	–	–	﹤0.01%	3344
2017 Q4	$61K	Sell	4 -1	-20%	-$23.1K	﹤0.01%	3264
2017 Q3	$126K	Buy	5 +2	+67%	+$61.5K	﹤0.01%	3155
2017 Q2	$139K	Sell	3 -3	-50%	-$164K	﹤0.01%	3074
2017 Q1	$461K	Buy	6 +2	+50%	+$162K	﹤0.01%	2426
2016 Q4	$344K	Hold	4	–	–	﹤0.01%	2554
2016 Q3	$456K	Buy	4 +2	+100%	+$250K	﹤0.01%	2348
2016 Q2	$174K	Buy	2 +1	+100%	+$118K	﹤0.01%	2699
2016 Q1	$184K	Buy	+1	New	+$107K	﹤0.01%	2597

Other funds holding NVIV

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

ICM

IMS Capital Management Portland, Oregon $217M AUM 18.69% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raymond James & Associates's NVIV Position: Q2 2018 in Review

Raymond James & Associates sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q2 2018, closing a stake of 4 shares — an estimated $40K sold.

Raymond James & Associates first reported a position in NVIV in Q1 2016 and held it in 9 quarters. The position peaked at $461K in Q1 2017. 17 funds tracked by Wall St. Rank hold NVIV as of Q2 2018.

Raymond James & Associates reported no remaining InVivo Therapeutics Holdings Corp position as of Q2 2018 after selling out during the quarter.
Raymond James & Associates sold 4 InVivo Therapeutics Holdings Corp shares in Q2 2018, an estimated $40K.
Raymond James & Associates first reported a position in InVivo Therapeutics Holdings Corp in Q1 2016 and held it in 9 quarters.
Raymond James & Associates's InVivo Therapeutics Holdings Corp position peaked at $461K in Q1 2017.
17 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q2 2018.

Based on Raymond James & Associates's 13F filing for Q2 2018, filed 14 Aug 2018.